“After a collaborative dialogue and productive engagement with the FDA we are encouraged by the acceptance of our BLA resubmission for RP1 in combination with nivolumab,” said Sushil Patel, Ph.D., CEO of Replimune (REPL). “We are currently partnering with the agency on the ongoing review to bring this important therapy to patients.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune upgraded to Market Perform from Underperform at BMO Capital
- Replimune’s Promising Study on Metastatic Uveal Melanoma: A Potential Game Changer?
- Replimune’s RP2 Study: A Promising Step in Cancer Immunotherapy
- Replimune’s Phase 3 Study on Advanced Melanoma: A Potential Game-Changer?
- Replimune’s Innovative Cancer Therapy: A Phase 1 Study Update